Clinical Trial Update: Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 study of Sacituzumab Govitecan in Japanese participants with advanced solid tumors is ongoing, including metastatic triple-negative breast cancer and …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hormone Receptor-positive Metastatic Breast Cancer
• Solid Tumor
• Triple-negative Breast Cancer
• Urothelial Cancer

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Gilead Sciences | Conditions: Advanced Solid Tumor, Metastatic Triple-Negative Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING